Free Trial
NASDAQ:PPD

PPD (PPD) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$47.28
$47.28
50-Day Range
$47.10
$47.41
52-Week Range
$31.54
$47.41
Volume
N/A
Average Volume
1.91 million shs
Market Capitalization
$16.61 billion
P/E Ratio
47.28
Dividend Yield
N/A
Price Target
N/A
PPD stock logo

About PPD Stock (NASDAQ:PPD)

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

PPD Stock News Headlines

Best Life: Beating baby blues
PPD: Three people shot on Victory Blvd.
See More Headlines
Receive PPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PPD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/27/2021
Today
6/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial Physical Research
Sub-Industry
N/A
Current Symbol
NASDAQ:PPD
Fax
N/A
Employees
26,000
Year Founded
N/A

Profitability

Net Income
$153.69 million
Pretax Margin
7.31%

Debt

Sales & Book Value

Annual Sales
$4.68 billion
Cash Flow
$1.99 per share
Book Value
($1.21) per share

Miscellaneous

Free Float
344,718,000
Market Cap
$16.61 billion
Optionable
Not Optionable
Beta
1.96
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Should I Buy PPD Stock? PPD Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in PPD, Inc.:

  • PPD, Inc. stock price has been steadily increasing, indicating positive market sentiment and potential for capital appreciation.
  • PPD, Inc. recently announced a strategic partnership with a leading pharmaceutical company, which could lead to increased revenue and market opportunities.
  • Analysts project strong earnings growth for PPD, Inc. in the upcoming quarters, reflecting a promising financial outlook for investors.
  • PPD, Inc. has a solid track record of delivering innovative solutions in the healthcare sector, positioning the company for long-term success and growth.
  • The company's recent expansion into emerging markets has opened up new revenue streams and diversified its business portfolio, reducing risk for investors.

Cons

Investors should be bearish about investing in PPD, Inc. for these reasons:

  • PPD, Inc. faces intense competition in the healthcare industry, which could impact its market share and profitability.
  • Regulatory changes in the healthcare sector may pose challenges for PPD, Inc., leading to increased compliance costs and operational hurdles.
  • Fluctuations in global economic conditions could affect PPD, Inc.'s revenue and earnings, making it susceptible to market volatility.
  • The company's high debt levels may limit its flexibility in pursuing growth opportunities and increase financial risk for investors.
  • Investors should closely monitor PPD, Inc.'s research and development pipeline to assess the potential impact of any setbacks on the company's future performance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 4, 2024. Please send any questions or comments about these PPD pros and cons to contact@marketbeat.com.

PPD Stock Analysis - Frequently Asked Questions

How were PPD's earnings last quarter?

PPD, Inc. (NASDAQ:PPD) released its quarterly earnings data on Wednesday, October, 27th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.05. The business earned $1.56 billion during the quarter, compared to analysts' expectations of $1.41 billion. PPD had a negative trailing twelve-month return on equity of 89.48% and a net margin of 6.11%. The business's quarterly revenue was up 26.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.15 EPS.

What other stocks do shareholders of PPD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PPD investors own include Cisco Systems (CSCO), Alibaba Group (BABA), Johnson & Johnson (JNJ), Salesforce (CRM), Pfizer (PFE), CVS Health (CVS), Intel (INTC), NVIDIA (NVDA), RTX (RTX) and Verizon Communications (VZ).

When did PPD IPO?

PPD (PPD) raised $1.5 billion in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 60,000,000 shares at $24.00-$27.00 per share. Barclays, J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird and William Blair acted as the underwriters for the IPO and BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird, William Blair and Drexel Hamilton were co-managers.

This page (NASDAQ:PPD) was last updated on 6/11/2024 by MarketBeat.com Staff

From Our Partners